title
PROPOSED GRANT AWARD
Department: Cook County Health
Grantee: Cook County Health
Grantor: Gilead INC
Request: Authorization to setup a new research award from Gilead
Purpose: The purpose of this research study is to determine how bictegravir (BIC), also known as GS9883, and lenacapavir (LEN) affect the HIV-1 infection in your body and compare it with B/F/TAF.
Grant Amount: $200,000.00
Grant Period: 6/1/2024 - 11/30/2027
Fiscal Impact: This Extramural Commercial contract with Gilead is a 4-year trial to look at The purpose of this research study is to determine how bictegravir (BIC), also known as GS9883, and lenacapavir (LEN) affect the HIV-1 infection in your body and compare it with B/F/TAF. The Contract amount of $200,000.00 is the maximum that could be earned and depends on services rendered and number of subjects enrolled in the clinical trial. We will look to start spending in June of 2024 and approximately spend 10-15% of the contract amount in year1 with ramp up spend in years 2-3, and ramp down spend, once the contract is near completion.
Accounts: N/A.
Concurrences:
The Budget Department has received all requisite documents and determined the fiscal impact on Cook County, if any.
Summary: This Extramural Commercial contract with Gilead is a 4-year trial to look at The purpose of this research study is to determine how bictegravir (BIC), also known as GS9883, and lenacapavir (LEN) affect the HIV-1 infection in your body and compare it with B/F/TAF
end